Revolution Medicines, Inc. Share Price & Technical Analysis
RVMD · $151.6 (-1.41%)
Healthcare / Biotechnology
$151.6
-1.41%
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS compa…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
6% return in May, 2% avg return in past 3 year May month.
74% return in 2026, 60% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 21% | 6% | -4% | 46% | 6% | – | – | – | – | – | – | – | 74% |
| 25 | -2% | -4% | -13% | 14% | -2% | -7% | 1% | 3% | 23% | 26% | 32% | 3% | 74% |
| 24 | -2% | 6% | 8% | 16% | 3% | 1% | 18% | -6% | 8% | 18% | 8% | -19% | 58% |
| 23 | 13% | 0% | -18% | 9% | 7% | 7% | -2% | 38% | -19% | -28% | 18% | 23% | 47% |
| 22 | -15% | -12% | 17% | -22% | -15% | 13% | 15% | -5% | -6% | 1% | 15% | 2% | -13% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$30.05B
P/E ratio
—
52W high
$156.3
52W low
$34.00
Volume
18,54,704
Beta
1.41
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Revolution Medicines, Inc. share price today?
- Revolution Medicines, Inc. (RVMD) last traded around $151.6 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RVMD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RVMD. Download the app for real-time alerts.
- How can I analyze Revolution Medicines, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.